Amgens Vectibix Trial Data Misses Primary Endpoint | Pharmaceutical Processing
Links shared publicly online about this topic.
- 956total visits
Amgens Vectibix Trial Data Misses Primary Endpoint | Pharmaceutical Processing
The data showed the addition of Vectibix to platinum-based chemotherapy did not result in a statistically significant improvement in overall survival, the primary endpoint, compared to chemotherapy alone
View full resource at pharmpro.com
Tags: Chemotherapy, Colorectal Cancer Medication, Pharma, Vectibix, Amgen
Most Recently Shared on August 11, 2010 at 1:51 pm By:
RT @PharmProEditor: #Amgen's Vectibix Trial Data Misses Primary Endpoint http://bit.ly/a9P7CV
Advertisement
